VeganHepPlusTM is Designed to Detoxify the Liver and Support Healthy Function
The American Association for the Study of Liver Diseases Predict Increase in Chronic Liver Disease Over the Next 25 Years
The Rise of Air Pollution Poses a Significant Threat to Liver Health
LAS VEGAS, NV, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTC: BDPT), a leading manufacturer and distributor of innovative, all-natural dietary supplements, highlights the importance of liver support as experts predict a steady rise of the most common form of chronic liver disease over the next 25 years.
Scientists presenting at The Liver Meeting, held by the American Association for the Study of Liver Diseases this week, predict nearly twice as many liver cancers and almost triple the need for liver transplantation by 2050. Researchers also focused on increases in air pollution and the impact this will have on liver disease.
Rising rates of obesity and diabetes are responsible for the expected increase in steatotic liver disease (formerly nonalcoholic fatty liver disease), which currently affects more than 30% of the global population.
To help support healthy liver function, BioAdaptives has announced the development of VeganHepPlusTM, a novel, all-natural, vegan supplement formula designed to promote liver detoxification and support healthy hepatic function.
Edward Jacobs, M.D., CEO at BioAdaptives, stated, “We are very pleased to announce the development of VeganHepPlusTM, part of BioAdaptives’ strategic offering of products designed to address a wider spectrum of common health issues.
“The liver is the body’s primary filter that traps and destroys harmful threats and manufactures important nutrients and chemicals. Support for a healthy liver includes a balanced diet, adequate vitamins, minerals, and biochemical substrates that are components of critical liver enzymes and other active molecules. The rising prevalence of pesticides and other environmental pollutants underscores the importance of providing comprehensive support for this vital organ.”
VeganHepPlusTM is formulated with natural ingredients derived from Traditional Chinese Medicine and Ayurvedic culture, known to be beneficial for these symptoms. Additional ingredients with anti-aging and anti-inflammatory features fortify this formula to broaden its overall effect.
About VeganHepPlusTM
VeganHepPlusTM is an all-natural, vegan formulation containing ingredients including milk thistle, for healthy liver function, Schisandra chinensis, an anti-aging and anti-inflammatory Traditional Chinese Medicine (TCM) supplement which counters fatigue, licorice, which also exhibits anti-inflammatory properties, Fucus vesiculosis, which may protect the liver from cytokine related injury and Platycodon grandiflorus, a popular TCM herb containing fatty acids such as linoleic acid, a variety of amino acids, vitamins, and multiple essential trace elements, as well as zinc, selenium and vitamin E.
About BioAdaptives, Inc.
BioAdaptives, Inc. develops and distributes natural plant- and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, antiviral activity, and immune system defense; resistance to stress; endurance; recovery from injury, illness, and exercise; and anti-aging properties. The Company’s current dietary supplement formulations are carefully selected from the best sources around the world and utilize proprietary methods of enhancing the bioavailability of nutrients. BioAdaptives’ current product line includes PrimiLungs™, PluriPain®, SleepEZ™, MindnMemory™ and Cell Rejuven™ for humans. The Company’s products for horses and dogs have also demonstrated increased general health, competitive performance enhancement, rejuvenation effects, and pain relief, as well as providing improvements in appearance. BioAdaptives’ wholly owned subsidiary, LiveStock Impact, Inc markets Canine Regen All In One™, Equine All In One™ and Equine All In One Plus™ for dogs and horses. LiveStock Impact, Inc. is also positioned to develop and market botanical drugs.
BioAdaptives’ common shares trade in the OTC market under the symbol BDPT. It has over 13,000 current shareholders. None of the statements about the Company’s products have been approved by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.”
Additional information can be found at www.shopbioadaptives.com or in our SEC filings at https://www.sec.gov/cgi-bin/browse-edgar?company=bioadaptives&owner=exclude&action=getcompany
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date after the date of this press release.
Contact
Investor Relations
BioAdaptives, Inc.
(702) 659-8829
info@bioadaptives.com
